Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant
Resource type
Journal Article
Authors/contributors
- Khoury, Ruby (Author)
- Grimley, Michael S. (Author)
- Nelson, Adam S. (Author)
- Leemhuis, Tom (Author)
- Cancelas, Jose A. (Author)
- Cook, Eleanor (Author)
- Wang, YunZu (Author)
- Heyenbruch, Daria (Author)
- Bollard, Catherine M. (Author)
- Keller, Michael D. (Author)
- Hanley, Patrick J. (Author)
- Lutzko, Carolyn (Author)
- Pham, Giang (Author)
- Davies, Stella M. (Author)
- Rubinstein, Jeremy D. (Author)
Title
Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant
Abstract
Reactivation or primary infection with double-stranded DNA viruses is common in recipients of solid organ transplants (SOTs) and is associated with significant morbidity and mortality. Treatment with conventional antiviral medications is limited by toxicities, resistance, and a lack of effective options for adenovirus (ADV) and BK polyomavirus (BKPyV). Virus-specific T cells (VSTs) have been shown to be an effective treatment for infections with ADV, BKPyV, cytomegalovirus (CMV), and Epstein-Barr virus (EBV). Most of these studies have been conducted in stem cell recipients, and no large studies have been published in the SOT population to date. In this study, we report on the outcome of quadrivalent third-party VST infusions in 98 recipients of SOTs in the context of an open-label phase 2 trial. The 98 patients received a total of 181 infusions, with a median of 2 infusions per patient. The overall response rate was 45% for BKPyV, 65% for cytomegalovirus, 68% for ADV, and 61% for Epstein-Barr virus. Twenty percent of patients with posttransplant lymphoproliferative disorder had a complete response and 40% of patients had a partial response. All the VST infusions were well tolerated. We conclude that VSTs are safe and effective in the treatment of viral infections in SOT recipients.
Publication
American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Pages
S1600-6135(24)00280-6
Date
2024-04-19
Journal Abbr
Am J Transplant
Language
eng
ISSN
1600-6143
Library Catalog
PubMed
Extra
PMID: 38643944
Citation
Khoury, R., Grimley, M. S., Nelson, A. S., Leemhuis, T., Cancelas, J. A., Cook, E., Wang, Y., Heyenbruch, D., Bollard, C. M., Keller, M. D., Hanley, P. J., Lutzko, C., Pham, G., Davies, S. M., & Rubinstein, J. D. (2024). Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, S1600-6135(24)00280-6. https://doi.org/10.1016/j.ajt.2024.04.009
DRUGS AND THERAPIES
ATC 2024 Top Papers in TID
Link to this record